To evaluate the potential ethnic differences in the pharmacokinetics (PK) and pharmacodynamics (PD) of evolocumab in Caucasian and Asian populations using population PK/PD modelling analysis.
Introduction
Evolocumab is a human monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) that is used for the therapeutic treatment of hypercholesterolaemia and the prevention of heart attack and stroke [1, 2] . The recommended therapeutic dose regimen for evolocumab is 140 mg once every 2 weeks (Q2W) or 420 mg once every month (QM), both administered subcutaneously (SC).
In human body, the liver is responsible for catabolism of plasma low-density lipoprotein (LDL). Hepatocytes express low-density lipoprotein receptor (LDL-R) that binds LDL and removes it from the plasma. Upon internalization, vesicles containing the LDL-LDL-R complex fuse with endosomes. PCSK9 is a protein that regulates the expression of LDL-R in the liver. It binds to LDL-Rs on the surface of the hepatocyte and is internalized with the LDL-LDL-R complex. The LDL-R-PCSK9 complex is routed to the lysosome for degradation, thereby preventing the cycling of LDL-R back to the hepatocyte surface. The reduced concentration of LDL-R on the surface of hepatocytes results in a lower rate of plasma LDL elimination. Evolocumab specifically binds to human PCSK9 and prevents it from interacting with LDL-R, which plays a critical role in the maintenance of the cellular and whole body cholesterol balance by regulating plasma LDL-cholesterol (LDL-C) levels [3] [4] [5] [6] [7] .
The pharmacokinetic (PK) and pharmacodynamic (PD) properties of evolocumab have been investigated in healthy subjects and subjects with hypercholesterolaemia using a target-mediated drug disposition (TMDD) model in previous research [8] . The drug disposition was characterized by a linear clearance, which is consistent with the common approach used for other monoclonal antibodies (mAbs). The time course of LDL-C reduction was described by an indirect response model with the elimination rate of LDL-C being modulated by unbound PCSK9. PK bridging studies are typically required by Asian regulatory agencies to extrapolate foreign clinical data for the development of new therapeutic agents. The International Conference on Harmonization (ICH) E5 was developed to facilitate the registration of medicines among ICH regions by recommending a framework for evaluating the impact of ethnic factors on a medicine's effectiveness and safety. However, ICH E5 also acknowledged that "although ethnic differences among populations may cause differences in the safety and/or efficacy of a medicine, many medicines have comparable characteristics and effects across ethnic populations" [9] . This paper describes a population PK/PD model analysis with the effects of ethnicity and target levels assessed for the PK of unbound evolocumab, unbound PCSK9 and a PD effect of lowering LDL-C. The objective of the present study was to evaluate the potential ethnic difference in the PK and PD of evolocumab between Caucasian and Asian subjects.
Methods

Clinical studies in the present investigation
Data from five Phase 1 studies were used to build the population PK/PD model. These studies included two Caucasian studies and three Asian studies, described briefly as follows. Only Caucasian and Asian (Japanese, Chinese) populations were chosen from the pooled dataset. Other ethnicities and races, such as Spanish, Mexican and Black, were excluded from the analysis. Intravenously administered subjects were also excluded (In study 20 080 397) since the approved route of administration was SC. The details of all the included clinical trials are presented in Table 1 .
All the included studies were conducted under the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference on Harmonisation. The protocols were approved by the independent ethics committee affiliated within each study and all subjects provided written informed consent.
PK/PD sampling schedule and assays
Venous blood samples were collected for the PK and PD measurements after the administration of the placebo or evolocumab. All PD blood samples were obtained after an overnight fast (> 10 h). The assays for unbound evolocumab, unbound PCSK9 and LDL-C have been described previously [8] . Blood sampling schedules for the assessment of unbound evolocumab, unbounded PCSK9 and LDL-C concentration are showed in Table 1 .
Structural model
Population PK/PD analysis was done using nonlinear mixedeffects model through a stochastic approximation approach. Within the model, PK analyses of unbound evolocumab and unbound PCSK9 were performed using a previously established TMDD model that incorporated the binding between evolocumab and PCSK9, turnover of PCSK9 and the elimination of the drug-target complex. Details on the model can be found in the 2016 publication by Gibbs et al. [8] . A one-compartment model with linear elimination was chosen to characterize the kinetics of free evolocumab with first-order absorption process (K a ) from the SC depot compartment to the centre compartment, central compartment volume distribution (V) and clearance (shown in Figure 1 ). The M6 method was used for unbound evolocumab, unbound PCSK9 and LDL-C when observations were below the limit of quantification (BLQ) by replacing first BLQ data with the lower limit of quantitation/2 and ignoring others [10] .
The PK of evolocumab in the depot (A depot ) after SC administration, the total drug amount in the central compartment (TDA) and the total ligand concentration (TLC) are described by equations 1-3, respectively.
The production and degradation of PCSK9 was described by a zero-order production rate constant (k syn ) and a first-order degradation rate constant (k deg ), where the rate constant ratio k syn /k deg represents the baseline PCSK9 level. Because of the lack of rich sampling data in the process of transition phase, the full TMDD model may induce overparameterized and unstable fitting. A quasi-steady-state approximation TMDD model were used to describe the binding of the drug and target to form a complex. In the quasisteady-state TMDD model, the binding rate is balanced by the sum of the dissociation and internalization rates. The steady-state constant (k ss ) equals the ratio of the sum of the complex internalization rate (k int , here representing the elimination of the complex) and the rate constant (k off ) to the drug-target association rate constant (k on ), where the KD is defined as the ratio of k off /k on .
The relationships between the total drug concentration (TDC; nmol l 
According to the steady-state approximation of the TMDD model, an indirect response model was used for PD to describe the inhibition effects of unbound PCSK9 on LDL-C [8, 11, 12] (Equation 7) :
Where k in and k out are the production rate constant (zeroorder) and degradation rate constant (first-order) of LDL-C, respectively. I max is the maximal inhibition effect due to PCSK9, fixed to 1; and IC 50 is the unbound PCSK9 concentration with an effect equal to 50% of I max .
Validation
After the final model was constructed, goodness-of-fit plots were created to evaluate the appropriateness of the model. A visual prediction check (VPC) based on 1000 Monte Carlo simulations was performed to validate the model's predictive performance for a single dose of 140 mg or 420 mg within the 5 th to 95 th percentile boundaries [13] . The jack-knife (leaveone-out) method was also used to test the model's sensitivity to each trial [14] .
Ethnic sensitivity analysis
During the model's establishment, ethnic-related covariates (ethnicity, body weight, baseline PCKS9 and baseline LDL-C, etc.) were screened by incorporating them into the basic model (forward method). The statistical significance of each was then tested using a likelihood ratio test. Covariates that produced significant changes (P < 0.05) in the objective function value (OFV, a decrease in OFV ≥3.84) were added to the final model. Boxplots were used to evaluate the impact of ethnicity on essential PK and PD parameters. Then, simulations of the relationship between time and change in LDL-C from baseline from the 420 mg single dose (only the 420 mg dose group was available in both the Asian and Caucasian studies) was performed based on the final established PK/PD model and compared with the real data.
For mAbs, body weight (impact on nonspecific elimination) and target expression level (impact on specific elimination) are generally the two factors that influence the PK/PD relationship. The correlation between baseline body weight and the main PK and PD parameters were tested using linear regression. The impact of target expression level on evolocumab PK/PD was analysed using simulations that were based on different baseline PCSK9 concentrations (healthy subjects = 3.72 nmol l -1 , hypercholesterolaemic subjects = 5.81 nmol l -1 ) under two labelling dose regimens.
Further simulations using singles doses of 70 mg and 420 mg administered SC were performed to explore the PK/PD effects of evolocumab at two extreme levels.
To further verify the results, the time-course of the LDL-C lowering effects of evolocumab following multiple SC doses Figure 1 Schematic of target-mediated drug disposition model. I max , maximal inhibition; IC 50 , PCSK9 concentration associated with 50% I max ; k a , absorption rate constant; k el , elimination rate constant; k syn , PCSK9 production rate constant; k deg , PCSK9 elimination rate constant; K D , dissociation constant; k int , evolocumab-PCSK9 complex elimination rate constant; k in , LDL-C production rate constant; k out , LDL-C elimination rate constant; PCSK9, proprotein convertase subtilisin/kexin type 9; LDL-C, low-density lipoprotein cholesterol Ethnic difference analysis of evolocumab were simulated based on the Asian hypercholesterolaemic subjects' PCSK9 levels (5.61 nmol l -1 ) at the two labelling doses (140 mg SC Q2W and 420 mg SC QM) [15] . These effects were then compared to the observed data from the Japanese evolocumab Phase 2 and phase 3 studies.
Software
Model estimation and simulation was performed using NONMEM 7.3 (ICON Development Solutions, USA). Model evaluation and plotting was done using R software (version 3.4.1, The R Foundation of Statistical Computing, Vienna, Austria).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [16] , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2017/18 [17] .
Results
Patient/subject characteristics
A total of 74 Caucasians (40 healthy subjects, 34 hypercholesterolaemic subjects) and 69 Asians (all healthy subjects, no hypercholesterolaemic subjects) were included in our population PK/PD modelling analysis. Supplemental Table S1 shows the subject demographics. 
Structural model
A TMDD model was used to describe the PK of evolocumab based on the linear elimination profile of evolocumab and consequent reductions in unbound PCSK9. The Population PK/PD parameter estimates for the model are presented in Table 2 . The relative standard error (RSE) for all PK parameters was acceptable, with a range of 4-21.3%. The inter-subject variability for random effects associated with the PK model parameters was moderate, ranging from 16.4% to 29.6%. Due to differences in the baseline PCSK9 concentration of healthy (Caucasian: 3.72 nmol l -1 , Asian: 3.42 nmol l -1 ) and hypercholesterolaemic subjects (5.82 nmol l -1 ), the parameter θ (0.569) was introduced to describe the fold change in baseline PCSK9 for healthy subjects compared to hypercholesterolaemic subjects. The proportional residual variability for evolocumab and PCSK9 was 0.032 (RSE = 3.9%) and 0.076 (RSE = 5.7%), respectively. An indirect response model described the turnover of LDL-C in which PCSK9 inhibited the elimination of LDL-C. The decreasing PCSK9 levels due to evolocumab administration led to the increased elimination of LDL-C, thereby decreasing serum LDL-C levels. The final PK/PD model described the time-course of the LDL-C concentration with a precise estimation of the fixed effects parameters, ranging from 5.2% to 14.9%. The value of I max was fixed to 1, based on a previous study [8] . The proportional and additive residual variabilities were 0.006 (RSE = 18.8%) and 83.9 (7.2%), respectively.
Model validation
The goodness-of-fit plots for unbound evolocumab, unbound PCSK9 and LDL-C are shown in Figure 2 . There was good agreement between the observations and the population predictions/individual predictions. Moreover, the observations and predictions from the model did not vary significantly between the Asian and Caucasian populations.
The VPC (Figure 3 ) for the single doses of 140 mg SC and 420 mg SC indicated good agreement between the simulations and the observed data for the PK (unbound evolocumab and unbound PCSK9) and PD (LDL-C) model.
The jack-knife method was used to test the impact of each study on the model parameters. The results showed that the distribution of most parameters was stable and only slightly affected by the individual studies (Figure 4 ).
Ethnic sensitivity analysis
Ethnic sensitivity analyses were performed for both PK and PD. During the establishment of the model, ethnic-related effects were explored as covariates in the population PK/PD model, but none were significant compared to the reduced model that was not adjusted for ethnicity. Essential PK/PD parameters, including K a , clearance, volume and IC 50 , did not show significant differences (P > 0.05) between the Caucasian and Asian populations (see Figure 5 ). In Figure 6 , there were no noticeable differences in the evolocumab PK/PD relationship between the Caucasian and Asian populations at a single dose of 420 mg and that the observed values were normally distributed around the simulation curve.
As shown in Figure 7 , none of the main PK/PD parameters were significant correlated with body weight which is an important factor for the nonspecific elimination of mAbs. The PK profiles of both evolocumab and PCSK9 and the PD profiles were simulated based on different PCSK9 expression levels (Caucasian hypercholesterolaemic subjects: 5.82 nmol l -1 , Caucasian healthy volunteers: 3.72 nmol l -1 ).
When the drug is administered SC at 140 mg Q2W, a 3-fold difference in unbound PCSK9 concentration (hypercholesterolaemic subjects vs. healthy subjects = 1.86 vs. 0.64) induced slight decreases of 30% and 4% in unbound evolocumab and LDL-C lowering, respectively (Figure 8 ).
When the dose was changed to 420 mg QM, the difference in unbound PCSK9 concentration increased 3.64-fold, following decreases of 8.5% and 7.3% in the respective free drug concentrations and PD effects. For the single doses of 70 mg or 420 mg of evolocumab, the unbound PCSK9 rapidly dropped below the BLQ value (0.28 nmol l -1 ). The greatest changes in LDL-C from baseline were 72.3% and 57.4%, respectively ( Figure 9 ). Increasing the C max of unbound evolocumab by a factor of 9 only led to a 14.9% increase in the maximum PD effect. The prediction result for lowering LDL-C in Asian hypercholesterolaemic subjects is shown in Figure 10 . The simulated effect-time curves following two therapeutic dose regimens were consistent with the Phase 2 YUKAWA Study and the Phase 3 study [15, 18] .
Discussion
The necessity of PK bridging studies for mAbs has been a subject of discussion because the inherent characteristics of IgG are considered ethnically insensitive [19] . Several investigations have been performed to establish development strategies in different regions for new therapeutic antibodies and assess the need for bridging PK/safety studies prior to joining global studies [19] [20] [21] . Unlike most small molecules, the disposition of mAb is often target-mediated, and its elimination occurs through both nonspecific and specific catabolic routes [22] [23] [24] . A review of 24 mAb therapeutics that had been evaluated by both Japanese and non-Japanese PK studies showed little difference in the PK of these mAbs between Japanese and non-Japanese subjects. Even for mAbs that did show marginal PK differences between ethnic groups, the treatment doses used in subsequent clinical studies in Japan were the same as the approved doses used in the USA [19] [20] [21] . This is because the observed differences in PK were either due to differences in body weight or in target expression, neither of which require a different dose if within a safety margin [21] . Additionally, dietary factors would not be expected to affect their systemic exposure since mAbs are administered intravenously or parenterally [20] .
To evaluate the potential impact of ethnic factors on evolocumab quantitatively, we investigated its PK and PD markers in Caucasian and Asian healthy subjects as well as in Caucasian hypercholesterolaemic subjects following the administration of both single and multiple doses. A previously established TMDD model together with an indirect response model successfully described the PK/PD relationship Table 2 Population pharmacokinetic/pharmacodynamic parameters estimation for evolocumab using target-mediated drug disposition model Residual error
BASE LDL-C , baseline LDL-C; BASE PCSK9 , baseline proprotein convertase subtilisin/kexin type 9 (PCSK9); CL, clearance; IC 50 , concentration associated with half-maximal inhibition; I max , maximal inhibition; k a , absorption rate constant; k deg , PCSK9 degradation rate constant; k int , complex elimination rate constant; k out , elimination rate constant for LDL-C; k ss , steady-state constant; SE, standard error of the estimate; V, volume of distribution; %RSE, relative standard error of the estimate calculated as (SE/Estimate) ·100; θ, fold change in baseline PCSK9 for healthy subjects vs. statin-treated patients a The intersubject random variance was fixed at 0 for this parameter.
of evolocumab. The population PK/PD model parameter estimates agreed well with previous investigations, and none of the ethnic related factors were found to be significant in changing the PK/PD profiles. The body weight and target expression level were already known to be important factors in the nonspecific and specific elimination of mAbs. A series of simulations based on different body weights and PCSK9 level scenarios suggested that there were no significant changes in the PK, PD and PK/PD of evolocumab. Evolocumab is eliminated by endogenous IgG catabolic routes and by binding to its target (PCSK9). Both elimination pathways were evaluated in this study with respect to reducing LDL-C. The general processes of nonspecific clearance are balanced between endosomal salvage, mediated by a saturable neonatal Fc receptor (FcRN) and lysosomal degradation [25, 26] . Several reports have described ethnic differences for FCGRT and FcγR [27] [28] [29] [30] , but their impacts on the clearance of mAbs remain unknown. A more detailed PK mechanism, such as endogenous IgG and mAbs elimination via FcRN and FcγR, might be of academic interest.
The linear clearance of evolocumab was 0.282 and 0.279 l day -1 in Caucasian and Asian populations, respectively, which showed that there were few ethnic differences in the nonspecific elimination of evolocumab, although we only evaluated the total drug clearance due to limited data. For specific elimination, PCSK9 levels may be a factor in determining evolocumab PK. The estimated PCSK9 levels in Caucasian and Asian hypercholesterolaemic subjects (5.659 nmol l -1 in Caucasian and 5.283 nmol l -1 in Asian)
were consistent with those observed in previous clinical trials with the between-subject variability fixed at 0%. In comparing the in vivo kss to the in vitro KD (KD = 8.0 pmol l -1 ), kss is always greater than KD within the range up to 30 times. Ethnic differences were not found for the PCSK9 production rate constant or the evolocumab-PCSK9 complex elimination rate constant. This indicates that, from a PK perspective, it may be particularly difficult to expect clinically meaningful results from bridging safety studies for mAbs because the PK of mAbs is dependent on the target levels that can be measured in diagnostic practice. The effect of evolocumab on LDL-C concentration was also investigated using an indirect response model. Because the three Asian clinical studies (Studies 20 120 121, 20 120 134 and 20 150 353) were all single dose studies, the model validations via VPC were conducted at the single doses of 140 and 420 mg to include both the Asian and Caucasian subjects. We evaluated the relationships between the observations and the simulation Figure 3 Visual prediction assessment of 140 mg SC (upper) and 420 mg SC (lower), median ± 90% prediction interval of simulated pharmacokinetics and pharmacodynamics (solid blue line and blue-shaded region, respectively, after 1000 times simulation) and observed data (black point), red line for observed median Figure 4 Jack-knife validation. Bar charts of the typical parameter values obtained from the final model using the leave-one-out method. The abscissa represents the study number dropped from the full data. The red bar represents parameters obtained when no study was excluded. k a , absorption rate constant; CL, clearance; VC, volume of distribution in central compartment; IC 50 , concentration associated with half-maximal inhibition curves of the mean percentage change in LDL-C following the dose regimens. No noticeable differences were found between ethnic cohorts and all observations were normally distributed around the simulation curves. Simulations of the PK/PD relationship based on the approved evolocumab labelling doses were also performed. In addition to the comparability in PK and PCSK9 target levels between the two ethnicities, the ability of evolocumab to lower LDL-C was also consistent. Since no Asian subjects with hypercholesterolaemia were included in our modelling and simulation, we used the PK/PD model to predict the 12-week LDL-C lowering from the literature reporting the PCSK9 values of Asian hypercholesterolaemia subjects. The results were almost identical to those of the Japanese Phase 2 YUKAWA study and the Phase 3 study [15, 18] . This indicates that the efficacy of evolocumab in different patient populations can be predicted using the present population PK/PD model. The PD effect was also compared for extreme dose differences. When the administered dose was increased from 70 to 420 mg, the C max of unbound evolocumab increased from 57.7 to 524 nmol l -1 . This increase only resulted in a 15% improvement of the maximum LDL-C lowering effect. This phenomenon was caused by the high molar ratios of evolocumab to PCSK9 (10:1 under 70 mg and 100:1 under 420 mg). This indicates that even if a large difference in PCSK9 exists between different ethnic groups, almost all PCSK9 will quickly bind to evolocumab and remain at a relatively low level due to
Figure 5
The relationship between ethnicity and the main pharmacokinetic/pharmacodynamic parameters. k a , absorption rate constant; IC 50 , concentration associated with half-maximal inhibition Figure 6 Relationship between low-density lipoprotein cholesterol(LDL-C) lowering of evolocumab by ethnicity [Asian (blue) and Caucasian (red) and simulation line (green)]
Figure 7
The relationship between bodyweight and the main pharmacokinetic/pharmacodynamic parameters. k a , absorption rate constant; IC 50 , concentration associated with half-maximal inhibition Figure 8 Model simulation, comparison of the pharmacokinetic/pharmacodynamic relationships between different proprotein convertase subtilisin/kexin type 9 (PCSK9) expression levels (Caucasian healthy volunteers = 5.82 nmol l -1 , Caucasian hypercholesterolaemic subjects = 3.72 nmol l -1 ) using two labelling dosages (left: 140 mg every 2 weeks subcutaneously; right: 420 mg every month subcutaneously). LDL-C, low-density lipoprotein cholesterol
Ethnic difference analysis of evolocumab the large molar concentration difference. This result will not significantly change the LDL-C lowering effect of evolocumab. Based on these analyses, studies on evolocumab in healthy Japanese and Chinese volunteers might not have been necessary for providing additional insights into the PK and PD properties beyond those obtained in prior Caucasian Phase I studies. Arguably, the present study also justifies the waiver of PK studies in Asian hypercholesterolaemic subjects since such studies have been performed in the USA and PCSK9 levels did not differ between the different ethnic groups. From a safety perspective, since there is no apparent off-target toxicity for evolocumab, PK/safety studies in healthy volunteers and patients may be unnecessary.
In conclusion, we evaluated the ethnic differences in evolocumab PK profiles between Caucasian and Asian subjects using a TMDD-based population PK model. No clinically relevant differences were found for the PK and PD properties, indicating that there is no need to modify the dose or dose regimens for Asian populations.
Figure 9
Model simulation, time-concentration curve and time-efficacy curve for doses of 70 mg and 420 mg administered subcutaneously. LDL-C, low-density lipoprotein cholesterol Figure 10 Model prediction for low-density lipoprotein cholesterol (LDL-C) lowering based on the Asian PCSK9 level at baseline for doses of 140 mg every 2 weeks (Q2W; red line) and 420 mg every month (QM; brown line). The solid points are the mean changes in LDL-C from the Japanese Phase 2 and Phase 3 studies
